News

PGEC

IPO Report: Fate Therapeutics (FATE)

Francis Gaskins | Equities.com |

Fate Therapeutics ($FATE) is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including


Sponsored Financial Content

Market Movers